文献速递临床试验与 GCP基础与转化研究

黄连解毒汤治疗高脂血症的随机双盲安慰剂对照试验方案

Efficacy of Hwangryunhaedok-tang (Huang-lian-jie-du-tang, Oren-gedoku-to) for patients with hyperlipidemia: a study protocol for a randomized, double-blind, placebo-controlled, parallel, investigator-initiated clinical trial.
PubMed 文献 · Trials · 2020-08-27

BACKGROUND: The prevalence of hyperlipidemia continues to increase due to aging and lifestyle changes. Statins are currently used as the first choice for treating hyperlipidemia, but are limited by adverse reactions.…

要点

  • 主要结局为治疗8周时低密度脂蛋白胆固醇水平。
  • 次要结局涵盖血脂、动脉硬化、血糖、血压、生活质量及寒热证候等。

核心结论

  • 该先导试验旨在探索黄连解毒汤治疗高脂血症的可行性、有效性和安全性,结果可能为未来大规模确证性临床试验奠定基础。

研究设计与样本

  • 在韩国大田开展的随机、双盲、安慰剂对照、平行、研究者发起的先导性临床试验方案。
  • 干预为每日服用三次、持续8周,随后随访4周。

主要发现

  • 主要结局为治疗开始后8周时的低密度脂蛋白胆固醇水平。
  • 次要结局包括其他血脂参数、动脉粥样硬化生物标志物、动脉硬化程度、血糖参数、血压、人体测量参数、健康相关生活质量及寒热证候变化。
  • 通过不良事件和实验室检查评估安全性,并通过下一代测序探索干预前后肠道菌群变化。

关键数值与推荐

  • 主要结局指标为治疗8周时低密度脂蛋白胆固醇水平。

临床怎么用

  • 该方案尚处于先导试验阶段,结果未报告,暂不能形成临床推荐。

局限性

  • 原文未报告该方案的研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of hyperlipidemia continues to increase due to aging and lifestyle changes. Statins are currently used as the first choice for treating hyperlipidemia, but are limited by adverse reactions. Hwangryunhaedok-tang (HHT) has received attention as a promising intervention for hyperlipidemia through a few experimental and clinical trials. This study aims to explore the feasibility, effectiveness, and safety of HHT for hyperlipidemia treatment. METHODS: This is a study protocol for a randomized, double-blind, placebo-controlled, parallel, investigator-initiated, pilot clinical trial held in Daejeon, Republic of Korea. Thirty patients with hyperlipidemia will be randomly allocated to HHT or placebo granule groups in equal proportions. Participants will be administered HHT or placebo granules three times per day for 8 weeks and followed up for another 4 weeks. The primary outcome is low-density lipoprotein cholesterol at 8 weeks from the commencement of treatment. Other blood lipid parameters, biomarkers of atherosclerosis, the degree of arteriosclerosis, blood glucose parameters, blood pressure, anthropometric parameters, health-related quality of life, and the changes in the general symptoms of cold and hot patterns will be measured as secondary outcomes. Adverse events and laboratory test results will be investigated to assess the safety. Changes in the gut microbiome before and after intervention will also be assessed as an exploratory outcome through next-generation sequencing. Data will be recorded in electronic case report forms and analyzed using SAS® Version 9.4. DISCUSSION: This is a rigorously designed pilot clinical trial to explore the effect and safety of Hwangryunhaedok-tang compared to placebo control for patients with hyperlipidemia, thereby potentially facilitating better management of hyperlipidemia. The results of this pilot study could form the foundation for a future large-scale, confirmatory clinical trial. TRIAL REGISTRATION: Clinical Research Information Service KCT0004564 . Registered on December 18, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee B, Han K, Park HJ, et al. Efficacy of Hwangryunhaedok-tang (Huang-lian-jie-du-tang, Oren-gedoku-to) for patients with hyperlipidemia: a study protocol for a randomized, double-blind, placebo-controlled, parallel, investigator-initiated clinical trial. Trials. 2020. PMID: 32854756. doi:10.1186/s13063-020-04695-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。